Anti-Human IL23A Recombinant Antibody (Brazikumab) (CAT#: TAB-008ML)

Figure 1 Atients receiving MEDI2070 had greater reductions in serum IL22 levels than did patients receiving placebo.

Percent change from baseline in serum IL22 levels in MEDI2070 and placebo groups (A) and percentage of patients with clinical response (B) and with clinical remission (C) over time, by baseline serum IL22 levels. Error bars represent median absolute deviation (MAD).

Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S.,... & Li, J. (2017). Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology, 153(1), 77-86.

Figure 2 The serum MEDI2070 concentration levels between responders and nonresponders at weeks 8, 12, and 24.

Individual concentration of MEDI2070 by CDAI response (A, B) and CDAI remission (C, D) during the double-blind phase (A, C) and the open-label extension phase (C, D).

Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S.,... & Li, J. (2017). Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology, 153(1), 77-86.

Figure 1 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in SDS-PAGE

SDS-PAGE analysis of TAB-008ML in non-reduced (Lane 1) and reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 130-180 kDa.

Figure 2 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in SEC-HPLC

HPLC analysis of TAB-008ML shows the purity is>95%.

Figure 3 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in WB

Western blot analysis was performed by loading 0.1 µg (lane 1), 0.3 µg (lane 2), and 0.6 µg (lane 3) recombinant human IL23 protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least 1 hour. Membranes were probed with Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) at a dilution of 1:500 overnight at 4°C on a rocking platform. Then probed with SA-HRP secondary antibody. Chemiluminescent was detected.
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)

Figure 4 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in DB

Dot Blot analysis of TAB-008ML was performed by coating with human IL4R protein antigen.
TAB-008ML incubation concentration: 2 ng/μL.
The secondary antibody: SA-HRP

Figure 5 Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML) in ELISA

ELISA analysis of TAB-008ML was performed by coating with recombinant human IL23a antigen. Then blocked with BSA and incubated with Anti-Human IL23A Therapeutic Antibody (Brazikumab) (TAB-008ML). The SA-HRP as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.